NDA 021807 · Mayne Pharma Commrcl
Soltamox
Tamoxifen Citrate · Oral
Last checked: Nov 19, 2026Latest source record: Apr 8, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Oct 29, 2005
Approved uses
2
Original approval plus efficacy supplements
Registered trials
564
199 Phase 3, 60 recruiting
FAERS reports
5,782
4,458 serious, 477 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: UTERINE MALIGNANCIES and THROMBOEMBOLIC EVENTS Serious and life-threatening events from the use of SOLTAMOX include uterine malignancies, stroke, and pulmonary embolism [see Warnings and Precautions (5.1 , 5.2) ] . Fatal cases of each type of event have occurred. Incidence rates per 1000 women-years for these events were estimated from the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 trial in women at high risk for breast cancer [see Clinical Studies (14.4) ] : Endometrial adenocarcinoma: 2.20 for tamoxifen vs. 0.71 for placebo Uterine sarcoma: 0.17 for tamoxifen vs. 0.04 for placebo Stroke: 1.43 for tamoxifen vs. 1.00 for placebo. Pulmonary embolism: 0.75 for tamoxifen versus 0.25 for placebo. Discuss the potential benefits of tamoxifen versus the potential risks of these serious events with women at high risk for breast cancer and women with ductal...
What it is approved for
From the label in effect Nov 29, 2021.
SOLTAMOX is an estrogen agonist/antagonist indicated: For treatment of adult patients with estrogen receptor-positive metastatic breast cancer ( 1.1 ) For adjuvant treatment of adult patients with early stage estrogen receptor- positive breast cancer ( 1.2 ) To reduce risk of invasive breast cancer following breast surgery and radiation in adult women with ductal carcinoma in situ (DCIS) ( 1.3 ) To reduce the incidence of breast cancer in adult women at high risk ( 1.4 ) 1.1 Metastatic Breast Cancer SOLTAMOX is indicated for the treatment of adult patients with estrogen receptor-positive metastatic breast cancer. 1.2 Adjuvant Treatment of Breast Cancer SOLTAMOX is indicated: for the adjuvant treatment of adult patients with early stage estrogen receptor-positive breast cancer to reduce the occurrence of contralateral breast cancer in adult patients when used as adjuvant therapy for the treatment of breast cancer. 1.3 Ductal Carcinoma in Situ In adult women with DCIS, following breast surgery and radiation, SOLTAMOX is indicated to reduce the risk of invasive breast cancer [see Boxed Warning and Clinical Studies (14.3) ] . 1.4 Reduction in Breast Cancer Incidence in Women at High Risk SOLTAMOX is indicated to reduce the incidence of breast cancer in adult women at high risk for breast cancer. [see Boxed Warning and Clinical Studies (14.4) ] .
Mechanism: Tamoxifen is an estrogen agonist/antagonist. Tamoxifen competes with estrogen for binding to the estrogen receptor, which can result in a decrease in estrogen receptor signaling-dependent growth in breast tissue. Tamoxifen has demonstrated antitumor activity against human breast cancer cell lines xenografted in mice. The drug has been shown to inhibit the induction of rat mammary carcinoma induced by dimethylbenzanthracene (DMBA) and to cause the regression of already established DMBA-induced tumors.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 25, 2018 Supplement 5 · Efficacy LabelMedication GuideLetter
- Oct 29, 2005 Original approval · Type 3 - New Dosage Form Medication GuideLabelReview
1 products under this application
- SOLTAMOX · TAMOXIFEN CITRATE EQ 20MG BASE/10ML · SOLUTION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tamoxifen" as an intervention, any sponsor and status, largest first.
- Tamoxifen in Treating Women With Breast CancerPivotal-lookingStatus unknown
University Hospital BirminghamAcademic, hospital or other
NCT00003678 · 20,000 participants (planned) · Start May 1991
Drug: tamoxifen citrate · For: Breast Cancer
Sites: Birmingham, United Kingdom
- Prolonged Tamoxifen Compared With Shorter Tamoxifen in Treating Patients Who Have Breast CancerPivotal-lookingStatus unknown
University of OxfordAcademic, hospital or other
NCT00003016 · 20,000 participants (planned) · Start Oct 1995
Drug: tamoxifen citrate · For: Breast Cancer
Sites: Oxford, United Kingdom
- Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal WomenPivotal-lookingCompleted
NSABP Foundation IncResearch network
NCT00003906 · 19,747 participants · Start May 1999 · Primary completion Dec 2005
Drug: Raloxifene; Tamoxifen · For: Breast Cancer
Sites: Huntsville, Alabama; Mobile, Alabama; Anchorage, Alaska · 516 sites in all
- Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)Pivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT00310180 · 10,273 participants · Start Apr 7, 2006 · Primary completion Mar 2, 2018
Drug: Anastrozole; Exemestane and 2 more · For: Breast Adenocarcinoma; Hormone Receptor Positive; Stage IA Breast Cancer AJCC v7 and 4 more
Sites: Anniston, Alabama; Birmingham, Alabama; Mobile, Alabama · 1,222 sites in all
- Raloxifene Use for The HeartPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00190593 · 10,000 participants · Start Jun 1998
Drug: raloxifene; placebo · For: Cardiovascular Diseases; Breast Neoplasms
Sites: Minneapolis, Minnesota
- Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast CancerPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00279448 · 9,779 participants · Start Jan 2002 · Primary completion Nov 2008
Drug: exemestane; tamoxifen · For: Breast Neoplasms
Sites: Marseille, France; Compiègne, France; Rennes, France · 59 sites in all
- Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By ExemestanePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00036270 · 9,779 participants · Start Aug 2001 · Primary completion Oct 2008
Drug: exemestane (Aromasin); tamoxifen + exemestane · For: Breast Neoplasms
Sites: Bessemer, Alabama; Birmingham, Alabama; Flagstaff, Arizona · 179 sites in all
- ATAC - Pharmacokinetics (PK) Sub-ProtocolPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00784862 · 9,358 participants · Start Jun 1998
Drug: Anastrozole; Tamoxifen · For: Breast Cancer
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue399
- nausea353
- diarrhoea283
- malignant neoplasm progression282
- arthralgia280
- pain248
- vomiting229
- dyspnoea227
- breast cancer223
- dizziness215
- headache207
- hot flush199
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 271 |
| 2005 | 237 |
| 2006 | 487 |
| 2007 | 455 |
| 2008 | 280 |
| 2009 | 485 |
| 2010 | 355 |
| 2011 | 419 |
| 2012 | 399 |
| 2013 | 60 |
| 2014 | 62 |
| 2015 | 110 |
| 2016 | 125 |
| 2017 | 150 |
| 2018 | 223 |
| 2019 | 220 |
| 2020 | 213 |
| 2021 | 271 |
| 2022 | 243 |
| 2023 | 219 |
| 2024 | 158 |
| 2025 | 187 |
| 2026 | 153 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Soltamox (Tamoxifen Citrate)
2024 spending
$525K
Beneficiaries
81
428 claims
Per beneficiary
$6,485
$4.54 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $47,828 |
| 2022 | $393,304 |
| 2023 | $469,196 |
| 2024 | $525,288 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Tamoxifen retinopathy.
Kaiser-Kupfer MI, Lippman ME · Cancer Treat Rep 1978 · Case Reports, Clinical Trial
- Adjuvant ovarian suppression in premenopausal breast cancer.
Francis PA, Regan MM, Fleming GF, et al. · N Engl J Med 2015 · Clinical Trial, Phase III, Multicenter Study
- Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Francis PA, Pagani O, Fleming GF, et al. · N Engl J Med 2018 · Multicenter Study, Randomized Controlled Trial
- Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.
Francis PA, Fleming GF, Láng I, et al. · J Clin Oncol 2023 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia.
DeCensi A, Puntoni M, Guerrieri-Gonzaga A, et al. · J Clin Oncol 2019 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Mayne Pharma Commrcl
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.